Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial

Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial

kidneycancer

4 years
374 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Neeraj Agarwal, MD of Huntsman Cancer Institute, University of Utah presents "Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial" at the 14th International Kidney Cancer Symposium.
Up Next Autoplay